[Asia Economy Reporter Hyunseok Yoo] Hugel, a global total medical aesthetic specialist company, announced that it held the 2021 1st quarter POA (Plan of Action) in a non-face-to-face online format on the 11th.
Hugel conducted the POA each quarter to gather domestic and overseas sales and marketing executives in one place to review quarterly performance and best practices, and to share goals and strategies for the next quarter.
About 80 employees participated in this POA held online, including the domestic sales department, marketing division, global business division, medical business division, and cosmetics division. They reviewed the 2020 achievements, shared the core strategies for 2021, and strengthened their commitment to execution.
The goal is to further solidify the domestic leading position of Botulinum toxin product "Botulax," which has been ranked number one domestically for five consecutive years, and the HA filler brand "The CHAUM," which has held the number one spot for two consecutive years. Additionally, they plan to accelerate overseas market expansion, led by China, the first-year launch market of the botulinum toxin product "Letybo" (export name to China).
Various marketing activities to support this have also been fully prepared. In the non-face-to-face sales environment caused by the COVID-19 pandemic, the company plans to focus on promoting differentiated brand value through evidence-based marketing strategies and full academic support to strengthen relationships with doctors and consumers.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
